Rafferty Asset Management’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-134,596
| Closed | -$6.95M | – | 1175 |
|
|
2022
Q3 | $6.95M | Sell |
134,596
-17,772
| -12% | -$735K | 0.07% | 225 |
|
|
2022
Q2 | $3.78M | Sell |
152,368
-73,036
| -32% | -$1.61M | 0.03% | 343 |
|
|
2022
Q1 | $5.65M | Buy |
225,404
+68,183
| +43% | +$1.92M | 0.03% | 356 |
|
|
2021
Q4 | $5.72M | Sell |
157,221
-44,855
| -22% | -$1.57M | 0.03% | 327 |
|
|
2021
Q3 | $3.46M | Sell |
202,076
-12,090
| -6% | -$188K | 0.02% | 406 |
|
|
2021
Q2 | $2.87M | Buy |
214,166
+156,386
| +271% | +$3.85M | 0.02% | 515 |
|
|
2021
Q1 | $2.96M | Buy |
57,780
+42,425
| +276% | +$2.55M | 0.02% | 505 |
|
|
2020
Q4 | $951K | Sell |
15,355
-25,920
| -63% | -$1.48M | 0.01% | 514 |
|
|
2020
Q3 | $2.26M | Buy |
41,275
+26,605
| +181% | +$1.43M | 0.03% | 375 |
|
|
2020
Q2 | $844K | Buy |
+14,670
| New | +$798K | 0.01% | 593 |
|
|
2020
Q1 | – | Sell |
-11,697
| Closed | -$463K | – | 853 |
|
|
2019
Q4 | $463K | Buy |
+11,697
| New | +$205K | 0.01% | 701 |
|
|
2019
Q3 | – | Sell |
-88,256
| Closed | -$821K | – | 867 |
|
|
2019
Q2 | $821K | Buy |
+88,256
| New | +$1.02M | 0.01% | 599 |
|
Other funds holding CCXI
Rafferty Asset Management's CCXI Position: Q4 2022 in Review
Rafferty Asset Management sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 134,596 shares — an estimated $6.95M sold.
Rafferty Asset Management first reported a position in CCXI in Q2 2019 and held it in 12 quarters. The position peaked at $6.95M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Rafferty Asset Management reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Rafferty Asset Management sold 134,596 ChemoCentryx, Inc. shares in Q4 2022, an estimated $6.95M.
- Rafferty Asset Management first reported a position in ChemoCentryx, Inc. in Q2 2019 and held it in 12 quarters.
- Rafferty Asset Management's ChemoCentryx, Inc. position peaked at $6.95M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Rafferty Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.